The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission. Preliminary Study
NCT ID: NCT01050010
Last Updated: 2011-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2010-04-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recently ultrasonography and MRI seem to be helpful in diagnosis and follow-up of rheumatoid arthritis.
Studies in patients with clinical remission are reporting 75 to 90% of persistent MRI and ultrasonography synovitis, 45% of cases with synovial activity.
To our knowledge, in such case few studies showed correlation between persistent imaging synovitis and structural radiographic progression.
On the other hand, no studies with extremity dedicated RMI in patients with remission are reported.
In this preliminary study, the investigators propose to evaluate in patients with rheumatoid arthritis remission and persistent dedicated MRI synovitis the structural radiographic progression at one year.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dedicated extremity MRI
Structural deterioration radiographic assessed by dedicated extremity MRI
MRI
dedicated extremity MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
dedicated extremity MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical remission (DAS 28 \<2,6 ou SDAI \<5) since 6 months before the inclusion
* Unchanged DMARds and /or biologic therapy since 6 months before the inclusion
* Unchanged corticosteroid (5 mg/day) since 3 months before the inclusion in patients treated with this therapy
* No contre-indication to the MRI
Exclusion Criteria
* Pregnant or breast-feeding women
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine ALBERT-SABONNADIERE, PhD
Role: PRINCIPAL_INVESTIGATOR
Nice University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de NICE
Nice, , France
Rheumatology Department, Nice University Hospital
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christine ALBERT-SABONNADIERE, M.D.
Role: primary
Christine ALBERT-SABONNADIERE, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-CIR-01
Identifier Type: -
Identifier Source: org_study_id